Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
452 participants
INTERVENTIONAL
2000-08-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
ATAC - Quality of Life Sub-Protocol
NCT00784680
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
NCT00286117
ATAC - Pharmacokinetics (PK) Sub-Protocol
NCT00784862
ATAC - Arimidex, Tamoxifen Alone or in Combination
NCT00849030
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARIMIDEX (anastrazole)
NOLVADEX (tamoxifen)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)
* Patients who might benefit from endocrine treatment prior to surgery
* Postmenopausal
* Signed written informed consent
Exclusion Criteria
* Patient unwilling to undergo surgery
* Any reason why the patient may not be able to conform to study requirements
* Any previous treatment for breast cancer
* Previous Tamoxifen use as a part of breast cancer prevention trials
* Not willing to stop taking drugs that affect sex-hormones such as HRT
* Previous history of breast cancer
* Previous history of invasive malignancy within the last 10 years
* Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results
* Treatment with an experimental drug within the last 3 months
* Risk of transmitting HIV, Hepatitis B or C
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Arimidex Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Santa Rosa, California, United States
Research Site
New Britain, Connecticut, United States
Research Site
Torrington, Connecticut, United States
Research Site
Springfield, Illinois, United States
Research Site
Mason City, Iowa, United States
Research Site
Baton Rouge, Louisiana, United States
Research Site
Pittsfield, Massachusetts, United States
Research Site
St Louis, Missouri, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Portland, Oregon, United States
Research Site
Austin, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Olympia, Washington, United States
Research Site
Antwerp, , Belgium
Research Site
Hasselt, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Rio de Janeiro, Rio de Janeiro, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Fortaleza, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Sheffield, , Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Chicoutimi, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Brno, , Czechia
Research Site
Nová Ves pod Pleší, , Czechia
Research Site
Olomouc, , Czechia
Research Site
Peské Budjovice, , Czechia
Research Site
Prague, , Czechia
Research Site
Praha-5, , Czechia
Research Site
Lyon, Cedex 08, France
Research Site
Avignon, , France
Research Site
Dijon, , France
Research Site
Limoges, , France
Research Site
Lyon, , France
Research Site
Marseille, , France
Research Site
Montpellier, , France
Research Site
Nice, , France
Research Site
Paris, , France
Research Site
Tours, , France
Research Site
Budapest, , Hungary
Research Site
Győr, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Szeged, , Hungary
Research Site
Szolnok, , Hungary
Research Site
Bologna, BO, Italy
Research Site
Cagliari, CA, Italy
Research Site
Monserrato, CA, Italy
Research Site
Kashiwa, Chiba, Italy
Research Site
Florence, FI, Italy
Research Site
Genova, GE, Italy
Research Site
Palermo, PA, Italy
Research Site
Reggio Emilia, RE, Italy
Research Site
Nagoya, Aichi-ken, Japan
Research Site
Chiba, Chiba, Japan
Research Site
Matsuyama, Ehime, Japan
Research Site
Fukuoka, Fukuoka, Japan
Research Site
Kitakyushu, Fukuoka, Japan
Research Site
Ōta, Gunma, Japan
Research Site
Fukuyama, Hiroshima, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Amagasaki, Hyōgo, Japan
Research Site
Isehara, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Kumamoto, Kumamoto, Japan
Research Site
Niigata, Niigata, Japan
Research Site
Ōita, Oita Prefecture, Japan
Research Site
Osaka, Osaka, Japan
Research Site
Sayama, Osaka, Japan
Research Site
Suita, Osaka, Japan
Research Site
Kitaadachi, Saitama, Japan
Research Site
Chūō, Tokyo, Japan
Research Site
Nijmegen, , Netherlands
Research Site
Sittard, , Netherlands
Research Site
The Hague, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15;106(10):2095-103. doi: 10.1002/cncr.21872.
Fujiwara Y, Takatsuka Y, Imoto S, Inaji H, Ikeda T, Akiyama F, Tamura M, Miyoshi K, Iwata H, Mitsuyama S, Noguchi S. Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen. Cancer Sci. 2012 Mar;103(3):491-6. doi: 10.1111/j.1349-7006.2011.02171.x. Epub 2012 Jan 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5395C00039
Identifier Type: -
Identifier Source: secondary_id
1033IL/0039
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.